

**Supplementary Table 1: Clinical characteristics of the retrospective normal collective and the prospective patient cohort.**

	Retrospective normal collective (n = 624)	Prospective patient cohort (n = 130)	p-value
<b>Sex</b>			
Female (n, %)	384 (62%)	73 (56%)	0.253
Male (n, %)	240 (38%)	57 (44%)	
<b>Age</b>	43	47	<b>0.004</b>
(mean, SD, range; in years)	(17.8; 18 - 85)	(17.7; 18 - 79)	
<b>TMT (mean, SD, in mm)</b>	8.6 (1.8)	7.8 (1.7)	<b>&lt;0.001</b>
<b>Grip strength*</b>	31.02 (10.93)	31.57 (12.05)	0.624
(mean, SD; in kg)			
<b>BMI (mean, SD)</b>	27.6 (5.4)	25.8 (6.1)	<b>0.003</b>

\* of the dominant hand Abbreviations: BMI: body mass index; SD: standard deviation; TMT: temporal muscle thickness.

**Supplementary Table 2: Patient characteristics subdivided with regard to their disease entities.**

	Neuro-Oncological (n = 44)	Cerebro-Vascular (n = 28)	CNS-Demyelinating (n = 15)	Psychiatric (n = 12)	Others (n = 31)
<b>Sex</b>					
Female	19(43%)	10 (36%)	5 (33%)	4 (33%)	19 (61%)
Male	25(57%)	18 (64%)	10 (67%)	8 (67%)	12 (39%)
<b>Age</b>	46	55	35	38	51
(mean, SD, range; in years)	(18.2; 18-78)	(17.3; 18-79)	(10.4; 18-52)	(12.3; 20-65)	(17.1; 18-78)
<b>TMT (mean, SD; in mm)</b>	7.4 (1.9)	7.6 (1.5)	7.2 (1.4)	8.4 (1.5)	8.2 (1.8)
<b>Grip strength *</b>	31.5 (12.6)	31.8 (9.4)	34.8 (14.9)	34.4 (11.7)	33.5 (11.7)
(mean, SD; in kg)					
<b>BMI (mean, SD)</b>	25.2 (5.3)	26.8 (6.0)	24 (4.6)	24 (5.7)	27.3 (7.7)
<b>Temporal wasting</b> (present; n, %)	12 (27%)	7 (25%)	1 (7%)	5 (42%)	8 (26%)
<b>Unintended weight loss</b> (n, %)	18 (41)	6 (21)	3 (20)	6 (50)	4 (13)
<b>NANO scale (mean, range)</b>	2 (2.48; 0 - 9)	1.7 (1.12; 0 - 5)	2.7 (2.52; 0 - 10)	1.2 (1.80; 0 - 5)	1.1 (1.93; 0 - 9)

\* dominant hand Abbreviations: CNS: central nervous system; BMI: body mass index; NANO: Neurological Assessment of Neuro-Oncology; SD: standard deviation; TMT: temporal muscle thickness.